WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H528517
CAS#: 134476-36-1
Description: BW-1370U87 is a monoamine oxidase A (MAO-A) inhibitor potentially for treatment of depression. BW-1370U87 elevates neurotransmitter amines in the brain over the same dose range at which it exhibits positive activities in animal models of depressive illness. BW-1370U87's mechanism of action follows simple competitive kinetics, so that an unusually high concentration of tyramine in peripheral tissues may displace the inhibitor from MAO-A sites in the intestine and liver.
Hodoodo Cat#: H528517
Name: BW-1370U87
CAS#: 134476-36-1
Chemical Formula: C14H12O3S
Exact Mass: 260.05
Molecular Weight: 260.307
Elemental Analysis: C, 64.60; H, 4.65; O, 18.44; S, 12.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BW-1370U87; BW 1370U87; BW1370U87; 1370U-87; 1370U 87; 1370U87
IUPAC/Chemical Name: 1-ethylphenoxathiine 10,10-dioxide
InChi Key: HQSRQKBSOOZLHH-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H12O3S/c1-2-10-6-5-8-12-14(10)18(15,16)13-9-4-3-7-11(13)17-12/h3-9H,2H2,1H3
SMILES Code: CCC(C=CC=C1OC2=C3C=CC=C2)=C1S3(=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 260.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Harfenist M, McGee DP, Reeves MD, White HL. Selective inhibitors of monoamine oxidase (MAO). 5. 1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site. J Med Chem. 1998 Jun 4;41(12):2118-25. PubMed PMID: 9622553.
2: Shockcor JP, Silver IS, Wurm RM, Sanderson PN, Farrant RD, Sweatman BC, Lindon JC. Characterization of in vitro metabolites from human liver microsomes using directly coupled hplc-nmr: application to a phenoxathiin monoamine oxidase-A inhibitor. Xenobiotica. 1996 Jan;26(1):41-8. PubMed PMID: 8851820.
3: Taylor LC, Johnson RL, St John-Williams L, Johnson T, Chang SY. The use of low-energy collisionally activated dissociation negative-ion tandem mass spectrometry for the characterization of dog and human urinary metabolites of the drug BW 1370U87. Rapid Commun Mass Spectrom. 1994 Mar;8(3):265-73. PubMed PMID: 8167371.
4: White HL, Ascher JA. Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor. Clin Neuropharmacol. 1993;16 Suppl 2:S25-33. Review. PubMed PMID: 8313394.
5: White HL, Ascher JA. Preclinical and early clinical studies with BW 1370U87, a reversible competitive MAO-A inhibitor. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:343A-344A. PubMed PMID: 1354041.
